Privia Health Group (NASDAQ:PRVA – Free Report) had its target price decreased by Truist Financial from $28.00 to $24.00 in a report issued on Wednesday morning, Benzinga reports. Truist Financial currently has a buy rating on the stock.
Several other equities analysts also recently weighed in on PRVA. JPMorgan Chase & Co. lowered their target price on Privia Health Group from $38.00 to $30.00 and set an overweight rating on the stock in a research report on Wednesday, March 6th. Canaccord Genuity Group reduced their target price on shares of Privia Health Group from $37.00 to $26.00 and set a buy rating for the company in a report on Friday, May 10th. TD Cowen lowered their price target on shares of Privia Health Group from $30.00 to $26.00 and set an outperform rating on the stock in a report on Friday, March 1st. Evercore ISI reduced their price objective on shares of Privia Health Group from $26.00 to $25.00 and set an outperform rating for the company in a research note on Wednesday, February 28th. Finally, Barclays started coverage on shares of Privia Health Group in a research note on Wednesday, March 6th. They set an equal weight rating and a $22.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average target price of $25.33.
View Our Latest Analysis on PRVA
Privia Health Group Trading Down 3.8 %
PRVA stock traded down $0.68 during trading on Wednesday, reaching $17.37. The stock had a trading volume of 1,136,681 shares, compared to its average volume of 961,556. Privia Health Group has a 52 week low of $16.90 and a 52 week high of $29.42. The firm has a market cap of $2.07 billion, a PE ratio of 115.80, a PEG ratio of 2.39 and a beta of 0.81. The stock’s 50 day moving average is $19.18 and its two-hundred day moving average is $20.89.
Privia Health Group (NASDAQ:PRVA – Get Free Report) last announced its earnings results on Tuesday, February 27th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The business had revenue of $440.80 million for the quarter, compared to analysts’ expectations of $425.81 million. Privia Health Group had a net margin of 1.11% and a return on equity of 3.13%. The firm’s quarterly revenue was up 21.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.14 earnings per share. On average, research analysts anticipate that Privia Health Group will post 0.24 EPS for the current year.
Insider Activity at Privia Health Group
In other Privia Health Group news, CFO David Mountcastle sold 3,933 shares of Privia Health Group stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $17.77, for a total value of $69,889.41. Following the sale, the chief financial officer now owns 262,279 shares of the company’s stock, valued at approximately $4,660,697.83. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CFO David Mountcastle sold 3,933 shares of the business’s stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $17.77, for a total value of $69,889.41. Following the sale, the chief financial officer now directly owns 262,279 shares in the company, valued at approximately $4,660,697.83. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Parth Mehrotra sold 12,219 shares of the company’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $18.42, for a total transaction of $225,073.98. Following the sale, the chief executive officer now owns 261,640 shares in the company, valued at $4,819,408.80. The disclosure for this sale can be found here. Over the last three months, insiders sold 49,390 shares of company stock valued at $897,700. Insiders own 14.20% of the company’s stock.
Hedge Funds Weigh In On Privia Health Group
A number of institutional investors and hedge funds have recently modified their holdings of the stock. New York State Teachers Retirement System boosted its stake in Privia Health Group by 33.8% during the third quarter. New York State Teachers Retirement System now owns 58,204 shares of the company’s stock worth $1,339,000 after buying an additional 14,700 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Privia Health Group by 13.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,829 shares of the company’s stock worth $479,000 after purchasing an additional 2,518 shares during the period. Strs Ohio lifted its stake in Privia Health Group by 42.9% in the third quarter. Strs Ohio now owns 20,000 shares of the company’s stock worth $460,000 after purchasing an additional 6,000 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its position in shares of Privia Health Group by 3.8% during the third quarter. Oregon Public Employees Retirement Fund now owns 30,300 shares of the company’s stock valued at $697,000 after buying an additional 1,100 shares during the period. Finally, TD Asset Management Inc grew its stake in shares of Privia Health Group by 23.0% during the third quarter. TD Asset Management Inc now owns 242,060 shares of the company’s stock valued at $5,567,000 after buying an additional 45,246 shares during the last quarter. Hedge funds and other institutional investors own 94.48% of the company’s stock.
Privia Health Group Company Profile
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
See Also
Before you consider Privia Health Group, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Privia Health Group wasn’t on the list.
While Privia Health Group currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
If a company’s CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Source: marketbeat.com
